Rebranded Health Innovation Networks, Biobanks and clinical trials get share of £650m UK funding earmarked to support research, manufacturing, skills development and access to diagnosis and treatment.

Report to government underlines need for faster, parallel evaluation of medtech and healthtech innovation and recommends bigger role for MHRA alongside work done by approved bodies on UKCA file processing.

This week, Medtronic said it would pay $738m for insulin patch firm EOFlow; Neuralink got an FDA OK for first-in-human trials; and UK agency NICE backed genetic tests for stroke patients and digital therapeutics for mental health conditions.

Life sciences and diagnostics group Thermo Fisher Scientific is encouraging suppliers to meet the same ambitious climate change targets that it has set for itself – mindful that Scope 3 emissions account for the vast majority of industry’s environmental footprint. But the drive for compliance must not compromise achievements made in the “S in ESG,” says corporate VP, CSR and sustainability, Meron Mathias.

The UK government’s first ever medtech strategy has received plaudits for its ambition. The diagnostics industry, while supportive of the intent, is waiting for more than just promises.

In Vivo Rising Leader Ashleigh Batchen has packed a lot of experience of medical device diagnostic regulatory issues into a few short years at the British In Vitro Diagnostics Association and before that the UK MHRA. Her advocacy offers vital support to the IVD industry at the busiest time in UK – and EU – regulatory history.